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Abstract 
The aggregation and deposition of α-synuclein in Lewy bodies is associated with the 
progression of Parkinson’s disease. Here Mass Spectrometry (MS) is used in combination 
with Ion Mobility (IM), chemical crosslinking and Electron Capture Dissociation (ECD) to 
probe transient structural elements of α-synuclein and its oligomers. Each of these reveals 
different aspects of the conformational heterogeneity of this 14 kDa protein. IM-MS analysis 
indicates that this protein is highly disordered, presenting in positive ionisation mode with a 
charge state range of 5 ≤ z ≤ 21 for the monomer, along with a collision cross section range 
of ~1600Å2. Chemical crosslinking applied in conjunction with IM-MS captures solution 
phase conformational families enabling comparison with those exhibited in the gas phase. 
Crosslinking IM-MS identifies 3 distinct conformational families, Compact (~1200 Å2), 
Extended (~1500 Å2) and Unfolded (~2350 Å2) which correlate with those observed in in 
solution. ECD-Fourier Transform –Ion Cyclotron Resonance Mass Spectrometry (ECD-FT-
ICR MS) highlights the effect of pH on α-synuclein structure, identifying the conformational 
flexibility of the N and C termini as well as providing evidence for structure in the core and at 
times the C terminus. A hypothesis is proposed for the variability displayed in the structural 
rearrangement of α-synuclein following changes in solution pH. Following a 120 hr 
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aggregation time course, we observe an increase in the ratio of dimer to monomer, but no 
gross conformational changes in either, beyond the significant variations that are observed 
day-to-day from this conformationally dynamic protein. 
Introduction 
Mass Spectrometry (MS) and the hybrid technique, Ion Mobility Mass Spectrometry (IM-
MS) have emerged as useful tools to investigate the early stages of aggregation of proteins 
implicated in protein misfolding diseases, and the multiple conformational families that co-
exist during the process 1. IM-MS can be used to measure heterogeneous samples (both in 
terms of stoichiometry and conformation), requires a low sample volume and allows a 
relatively short transfer time from bench to instrument. There are different forms of ion 
mobility instruments, however in this work we use drift tube based measurements (DT-IM-
MS). DT-IM-MS has been described in detail elsewhere 2, but briefly, it is an analytical 
technique that measures the time it takes a given m/z selected ion to pass through a drift cell 
filled with an inert buffer gas, under the influence of a weak electrostatic field. Under low 
field conditions, injected ions drift through the drift cell and are retarded as well as 
thermalized by collisions with the buffer gas. The mobility of an ion (K) is defined as the 
ratio between the drift velocity (vd), which is measured by measuring the arrival time and the 
applied electric field (E), and then converting to the reduced mobility (K0) by normalising the 
temperature and pressure of the drift gas. The mobility of any given ion is related to its 
rotationally averaged collision cross section (Ω) according to the Mason-Schamp equation 3 
where N is the number gas density, µ is the reduced mass of the ion and the buffer gas, and z 
is the charge on the ion. 
 =	 	
 



. 
	  Equation 1 
The aggregation of and the pre-fibrillar aggregates formed by β-2-microglobulin has been 
studied using IM-MS approaches by the  Vachet 4, Radford 5, 6 and Ashcroft groups 7-10. 
Bowers and co-workers have extensively studied amyloid-β 11-16 with contributions from 
Robinson 17. Other work has examined amylin 18-24, Tau 25 and a peptide from the amyloid 
disease associated protein Transthyretin or TTR 26. These constitute several of the 30 
different proteins which have been implicated as causal factors in human disease due to their 
inability to adopt or remain in their native conformational state 27. Such diseases are referred 
to as protein misfolding diseases due to the change in shape of the precursor protein, and 
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most neurodegenerative diseases fall into this category. The mechanism of dysfunction varies 
however, a common identifier is that normally soluble proteins form organised, insoluble 
fibrillar and oligomeric aggregates 27. Parkinsons Disease (PD) is one of these diseases and 
the protein involved is α-synuclein, a major constituent of the characteristic Lewy bodies, 
where it presents in an organised fibrillar state 28, 29.  
α-synuclein is a member of a subset of proteins known as, intrinsically disordered proteins 
(IDPs), defined as lacking (or having regions lacking) tertiary fold observable on the 
timescale of an NMR experiment. α-synuclein is a 140 amino acid protein encoded by a 
single gene, SNCA and in neurons it is localised predominantly in the presynaptic nerve 
terminals and nucleus 30. The exact function of α-synuclein is unknown however, it is 
theorised to be involved in synaptic function and neurotransmitter release 31. There is a large 
body of evidence indicating that α-synuclein exists as an unstructured monomer under a 
range of biophysical assays 31-34 and even in cells 35. However, the α-synuclein found in Lewy 
bodies has condensed to fibrillar aggregates rich in a β-sheet structure. The aggregation 
pathway has been described as containing multiple intermediate oligomer structures including 
spherical 36 and ring-shaped 31, 37 forms and is susceptible to pertubation, through changes to 
environmental factors. These factors include agitation, temperature and pH 38. The transition 
from native conformation to these amyloid deposits is therefore not a single step, nor a single 
pathway, and hence in order to understand the mechanisms at play it is critical to identify the 
species present at each step. Oligomers formed in the early stages of aggregation are most 
applicable as drug targets since they are reported to be the most toxic species that mediate 
neurodegeneration 7, 39. 
The Bowers 40, Kaltashov 41 and Grandori 42 have previously demonstrated the 
conformational plasticity of α-synuclein using mass spectrometry based approaches. All 
groups have reported the presence of multiple co-existing α-synuclein conformers under 
native conditions, including tightly folded and extended conformers 40-42. These studies have 
demonstrated the importance of solution conditions on the conformers presented by α-
synuclein, in particular pH dependence. Bernstein et al. and Frimpong et al. independently 
reported a shift to lower charged, more compact species at low pH 40, 41, whereas Natalello et 
al. showed a shift to higher charged, more extended conformers at basic pH 42. Bernstein et 
al. also noted the presence of dimer species at pH 2.5 and their absence at pH 7 40. In 
comparison, Frimpong et al. described the presence of dimer species at pH 2.5 to pH 8. The 
selective stabilisation of α-synuclein conformers via different alcohols has also been 
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displayed via MS 41, 42. Taking the data of these studies alone, it is clear that α-synuclein is 
extremely susceptible to environmental perturbations and even under tightly controlled 
conditions, significant variation in the data produced occurs. 
MS approaches have also been applied to study other aspects of α-synuclein for example to 
study the effect of fragments on aggregation 43, 44 and to characterise the influence of metal 
ion binding, on conformation and aggregation 42, 45-47. MS has been used to examine post-
translational modifications in α-synuclein, identifying phosphorylated species in CSF 48 and 
to investigate the effect of such post translational modifications on the behaviour of α-
synuclein 49, 50. Naturally occurring in vivo crosslinking of α-synuclein has been investigated 
with MS and implicated as both inducing and preventing aggregation 51, 52. Photo-induced 
crosslinking of α-synuclein in vitro has been used to probe the properties and cellular toxicity 
of oligomers and the di-tyrosine cross links were identified with mass spectral analysis 53. 
Hydrogen-Deuterium Exchange (HDX) can be used in conjunction with MS to monitor 
protein conformational dynamics 54, 55 and has been applied to the study of monomeric and 
low order oligomeric species of α-synuclein 56-59. These studies have confirmed that the α-
synuclein monomer is an unstructured solvent accessible protein, as a result of the rapid 
exchange which is seen across the entire sequence length 56, 57. Following the induction of an 
amyloid state, HDX has helped uncover structural changes experienced by α-synuclein, 56, 58 
but apparent inconsistencies in results from different groups highlights the dynamic nature of 
α-synuclein. Del Mar et al. provide evidence to suggest unprotected N and C termini with a 
protected central region 56 whilst Mysling et al. showed evidence for a protected N terminus, 
an unprotected C terminus and regions of protection within the central region 58. Furthermore 
HDX has also allowed the designation of two distinct oligomers with different levels of 
protection which may represent the  intermediates of two different aggregation pathways 59. 
HDXs ability to define structural information is backed by evidence from Lee et al., whose 
work on the binding of α-synuclein to lipids, highlights regions of protection in the N 
terminus, which correlates with the induction of α-helical structure in the α-synuclein N 
terminus following binding to a SLAS micelle, described previously 57, 60. 
MS has also enabled the study of the binding interactions of α-synuclein with a number of 
ligands including potential drug candidates, and in vivo partners 61, 62, including spermine 63, 
and dopamine64. In this study MS and IM-MS are applied; to investigate the conformational 
plasticity of α-synuclein, to detect low order oligomeric species and to follow the early stages 
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of aggregation. In vitro chemical crosslinking is used here in conjunction with IM-MS to 
capture transient conformational populations of monomeric α-synuclein. ECD-FT-ICR MS is 
also applied to investigate the structure of monomeric and dimeric species from different 
solution conditions. Our data is compared to data reported in previous studies. We use 
transmission electron microscopy to determine fibril formation under the solution conditions 
employed in MS studies. 
Experimental Methods and Materials  
a. Materials 
AR grade ammonium acetate, sodium phosphate, was purchased from Fisher Scientific 
(Loughborough, UK). BS3 crosslinker, sodium carbonate, sodium acetate, HEPES, potassium 
hydroxide and acetic acid were purchased from Sigma Aldrich (UK). Water was purified with 
an Arium 611 water purification system (Sartorius, Göttingen, Germany).  
b. α-synuclein preparation 
α-synuclein was expressed recombinantly, from a pT7-7 vector containing human α-
synuclein gene, kindly provided by Dr Jean-Christophe Rochet, Purdue University and 
purified as described previously 65; a Resource Q column (GE Healthcare Life Sciences, UK) 
was used. α-synuclein used for crosslinking, IM-MS and ECD-FT-ICR-MS analysis, was 
purified as described, concentrated using Vivaspin 6 centrifugal sample concentrators 
(MWCO 10kDa) (GE Healthcare Life Sciences, UK) and applied to a HiPrep 26/10 desalting 
column (GE Healthcare Life Sciences, UK) pre-equilibrated with 100mM ammonium acetate, 
flow rate 10mL/min. The eluent was lyophilised and stored at -80°C prior to use. Prior to 
analysis, if required, samples were thawed and dialysed into a 50mM ammonium acetate 
buffer solution (pH 7) overnight at 4°C using 3.5 kDa MW Slide-A-Lyzer Dialysis cassettes 
(Thermo Scientific, USA). Post-dialysis concentration was determined by a BCA assay 
(Pierce, Thermo Scientific, USA) prior to aliquoting.  
c. Aggregation procedure 
α-synuclein (70µM, 50mM ammonium acetate, pH 7) was incubated at 37°C with agitation at 
200rpm in an incubator shaker, a method adapted from the work of Hashimoto et al. and Fink 
et al. 
66, 67. Samples were incubated individually and at specified time points were removed 
and analysed immediately. The time taken to transfer the sample from incubation to nano-
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spraying tip was never more than 3 minutes. The samples were incubated for up to 120 hours 
and analysed at t = 0, 24, 48, 72, 96 and 120 hours. 
d. Crosslinking procedure 
For α-synuclein crosslinking experiments, the conditions were based on the manufacturers 
recommended conditions and the previously published work of Chen et al. 68 and primarily, 
Iglesias et al. 69 69. Here, four buffer conditions, each at 50mM, sodium acetate (pH 4), 
sodium phosphate (pH 6), HEPES (pH 8) and sodium carbonate (pH 10) were used. The pH 
of the HEPES buffer was modified with KOH. Since each crosslinking reagent has optimal 
operating conditions in terms of pH for maximum reactivity, by altering the pH during the 
crosslinker incubation, we are able to modulate the number of modifications. Lyophilised α-
synuclein was reconstituted in each buffer solution to which BS3 at 50:1 molar excess was 
added, final α-synuclein concentration, 100µM. Crosslinking reactions were incubated at 
room temperature for 1 hour. Reactions were quenched by the addition of 1M ammonium 
acetate. Samples were desalted via buffer exchange into 50mM ammonium acetate (pH 6.8) 
using Amicon Ultra centrifuge filters, MWCO 10kDa (Millipore). 
Nano-Electrospray Ionisation (nESI) was used for all MS and IMMS experiments, with the 
exception of ECD-FT-ICR MS. nESI tips were fabricated in-house using thin wall capillaries 
(ID 0.6mm) (World Precision Instruments, Inc, USA) using a Fleming/Brown micropipette 
puller (Sutter Instruments Co., USA). Samples were ionised via the insertion of platinum wire 
into the nESI tip to which a voltage was applied. 
e. Mass Spectrometry  
MS experiments were conducted on an Ultima API-US instrument (Micromass, Manchester, 
UK). Desalted α-synuclein was diluted with 50mM ammonium acetate to a concentration of 
70µM. MS was conducted in positive mode. Source conditions were kept as similar as 
possible to enable comparison: capillary voltage ~1.6kV, cone voltage 165V and source 
temperature 80°C. For pH variation experiments, the solution pH was modified by the 
addition of acetic acid.  
f. Drift Tube Ion Mobility Mass Spectrometry (DT-IM-MS) 
Drift Time Ion Mobility Mass Spectrometry measurements were performed on an in-house 
modified Q-ToF instrument (Micromass, Manchester, UK). The instrument has been 
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modified via the addition of a 5.1cm long copper drift cell and additional post source ion 
optics to carry out gas phase separation of protein ions based on the ion mobility, further 
instrument specifics are detailed elsewhere 70. Each experiment in the time course was 
performed in triplicate. Measurements were made at eight different drift voltages between 
60V and 10V. For aggregation and crosslinking IM-MS experiments, tuning conditions were 
kept as similar as possible: capillary voltage ~1.6kV, cone voltage ~ 98V and source 
temperature 80°C. The temperature and pressure of helium in the drift cell were on average 
302.4 K and 3.8 Torr, respectively, but are recorded and used to calculate mobilities for each 
experiment. 
Ion arrival time distributions (ATD) are recorded by synchronising the entry of each ion pulse 
into the drift cell with mass spectral acquisition. The mobility of the ion of interest was 
obtained from a linear plot of the average arrival time versus pressure/temperature, from 
which the rotationally-averaged Collision Cross Section (CCS) for each resolvable species at 
a given charge state was found using equation 1. Collision Cross Section Distributions 
(CCSD) were created by plotting the average CCS against peak intensity values and charge. 
Data analysis was conducted using Masslynx v4.1 (Waters Corporation, USA), Origin v8-9.5 
(OriginLab Corporation, USA) and Microsoft Excel (Microsoft, USA). 
g. ECD-FT-ICR-MS 
Lyophilised α-synuclein was reconstituted in 50mM ammonium acetate to a concentration of 
30µM. Samples were prepared at pH 3.5 and pH 6.8. pH was adjusted by addition of acetic 
acid. 
Protein samples were ionised and introduced to the mass spectrometer using a Triversa 
Nanomate (Advion, New York, USA). Spectra were acquired with a Bruker Solarix 12T 
FTICR Mass Spectrometer (Bruker Daltronics, Bremen, Germany). ECD-FT-ICR MS was 
performed after first acquiring a native mass spectrum by tuning source optics. Specific ion 
species were then isolated using the mass resolving quadrupole prior to MS/MS via ECD. For 
ECD, 1.7 A was applied to the cathode filament, 22 V to the lens, 1.2 V to the bias, and a 
pulse of between 15 and 20ms was employed. Fragmentation data is the sum of 70 
acquisitions. Data analysis was performed using DataAnalysis (Bruker Daltronics, Bremen, 
Germany). The SNAP 2.0 algorithm was used for peak picking and the matching of fragment 
peaks to calculated fragment masses was conducted by Prosight PTM (v1.0) 71. 
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Results and Discussion 
1. Mass Spectrometry experiments, contrasting day to day variations, and the effect 
of lowered pH with data from aggregation time courses.  
a. Day to day variations 
Here, MS has been used to differentiate the inherent conformational flux of α-synuclein from 
the effects of different ESI solution conditions.  
Figures 1A and B show MS spectra obtained from identically prepared samples taken under 
highly similar source conditions on the same instrument, approximately one month apart. In 
each case the spectra are predominantly due to the monomeric form of α-synuclein with a 
mass of 14453Da (cf. theoretical average mass, 14460Da). Both spectra also show evidence 
of higher order aggregates at low intensity. Comparison of the two spectra demonstrates the 
aforementioned conformational flux as well as the difficulty in acquiring reproducible data 
from this highly disordered protein. The most obvious change is seen in the relative 
population of different charge states as well as the distribution between monomer and higher 
order aggregates. In both cases, the protein exhibits a wide CSD, Figure 1B shows a CSD of 
5 ≤ z ≤ 19 for the monomeric species [aSyn +zH]z+, cf. a distribution of 5 ≤ z ≤ 20 in Figure 
1A. However, the most intense species in Figure 1A is at z = 17 (m/z = 851.6) and in Figure 
1B is z = 14 (m/z = 1033.9). Other differences in the relative intensities of ions can be 
observed: for example the z = 10 ion (m/z = 1447) has significant intensity in Figure 1A but 
is weaker in 1B, and here the z = 11 species (m/z = 1315.5) is much more abundant. Figure 
1A has multimodal distribution with at least three modes, z = 17, z = 14 and z = 11, by 
contrast, the data in Figure 1B has a predominantly monomodal distribution, centred on z = 
14. Figure 1B shows less intensity in peaks assigned as dimeric species. This can be clearly 
identified by comparison of the relative abundance of monomer and dimer peaks of Figure 
1A and Figure 1B and the less distinct multimodal distribution of Figure 1B. This change is 
accompanied by lowered intensities of the observed trimeric and tetrameric species. This data 
suggests that the low order oligomeric species identified (dimer to tetramer) vary in their 
presentation to the gas phase. Such fluctuations in spectra are typical for this protein 
following nano-ESI-MS analysis under similar experimental conditions. 
b. Change in pH 
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Figure 1C shows the CSD obtained following nano-ESI-MS at pH 3.5.  The drop in pH (cf. 
Figure 1A and B) results in a significant change in the way the protein presents in the gas 
phase environment. Despite the increased availability of protons, there is a dramatic decrease 
in the intensity of highly charged monomeric species and an increase in the intensity of lower 
charged species. This is evident when the width and the relative position of CSDs are 
compared. The monomer CSD shifts from 5 ≤ z ≤ 20 (Figure 1A) to 3 ≤ z ≤ 12 (Figure 1C) 
and presents in a multimodal CSD with populations centred on z = 10, z = 7. This 
modification is even more evident upon comparison of the dimeric species CSD, shifting 
from 10 ≤ z ≤ 23 (Figure 1A) to 7 ≤ z ≤ 13 (Figure 1C). This effect is seen for all multimeric 
species. 
This shift mirrors a change identified by Frimpong et al. where solution pH was dropped to 
pH 2.5 41. Our findings suggest that the protein has adopted a more compact structure, 
thereby decreasing solvent accessibility of protonatable sites and leading to lower charge 
states prevailing. This correlates with data from multiple physical techniques including IR, 
SAXs 72 and IM-MS 40, which demonstrate an induction of structure 72 and a partial collapse 
of the protein on lowering pH 40, both changes which decrease solvent accessibility and 
would decrease the average protonation state as shown here (Figure 1C).  
The induction of structure by pH may contribute to the increased detection of higher order 
species. The increase is clearly seen via comparison of the tetramer species present, z = 29 
(Figure 1A) and 15 ≤ z ≤ 17 (Figure 1C). The large increase in baseline noise is attributable 
to an increase in higher ordered aggregates73. The low sample pH combined with the low pI 
of α-synuclein (4.67), results in less protein-protein repulsion and is therefore an environment 
conducive to oligomer formation 34. This is supported by the depletion of the overall signal 
intensity. A similar effect is also seen under aggregating conditions (Supporting information 
Figure S1). 
c. MS following aggregation 
Figure 1D shows a mass spectrum obtained following 96 hours of aggregation at neutral pH. 
Initial comparison of Figures 1A and B to data in Figure 1D reveals similarities, the width of 
the CSDs of monomer, dimer and trimer species remain stable despite lengthy incubation 
under aggregation inducing conditions.  
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The aggregation of α-synuclein is presumed to be a nucleation dependent process and it has 
been suggested that the dimer is the aggregation nucleus 65, 74. As mentioned previously the 
dimer CSD remains similar to the t0 spectrum (Figure 1A) suggesting that the soluble 
population which must act as a feeder stock for the aggregates is comprised of forms of the 
protein that are conformationally dynamic, even when significant aggregates are present. This 
is in contrast to earlier work on aggregation of the peptide TTR (105-115) 26 where at a mid-
point in the aggregation time course a significant increase in the intensity of all observable 
higher order aggregates was reported followed by a decrease in the late stages and the 
persistence of dimer and tetramer species. However, it should be noted that the data in all 
panels in Figure 1 have been normalised to the base peak, the absolute intensity of the species 
in Figure 1D are depleted by almost 50%, compared to the species at t=0. We speculate that 
this depletion is the result of low order species being sequestered into much larger oligomers, 
the presence of which is confirmed by TEM (Supplementary information Figure S2) 
suggesting that this data is taken at a late point in the aggregation time course. Such large 
fibrils are not detectable by MS in this configuration. This depletion correlates with an 
increase in baseline noise, also indicative of aggregation (as shown in Figure 1C) and as 
previously reported 26. 
By plotting of the ratio of the sum of the absolute intensity of monomer and dimer peaks of 
the spectra at four time points along the aggregation course, we observe a shift in ion 
intensity to dimers with respect to time (Figure 2). The intensity of even charged dimer peaks 
will be affected by the mass coincident monomer peaks, although this will not significantly 
affect this qualitative analysis. The increase in monomer intensity at 96 hours, is similar to 
the rise in monomer intensity after 4 hours of aggregation of TTR(105-115), which we 
theorised to be the result of the destabilisation of higher order aggregates in the solution or 
upon desolvation 26. 
2. IM-MS – following conformations through an aggregation time course 
The in vitro aggregation of α-synuclein was conducted as described previously for up to 120 
hours, and followed by IM-MS. Collision Cross Section Distributions (CCSD) derived from 
arrival time distributions for selected monomer and dimer species are shown in Figure 3 (See 
Supplementary information Figure S3 for MS spectra). At t=0 for [aSyn+6H]6+ a narrow 
CCSD centred on ~1400 Å2 is observed with a small shoulder attributed to the mass to charge 
coincident species [(aSyn)2+12H]
12+ (Figure 3Ai). The large error bars indicate these species 
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are highly variable and they are no longer present in subsequent time point CCSDs for 
[aSyn+6H]6+. At subsequent time points the CCSD remains unchanged with the exception of 
the loss of the shoulder, perhaps a result of sequestration to higher order oligomeric species, 
the CCSD remains centred on ~1400 Å2 (Figure 3Aiii). For the higher charged monomeric 
species, [aSyn+10H]10+ the CCSD is much broader and centred on ~1800 Å2 (Figure 3Bi). At 
subsequent time points for the [aSyn+10H]10+ CCSD, the majority of species intensity 
remains centred on ~1800 Å2. Additionally, a shoulder is consistently present across all time 
points centred on ~2300 Å2 (Figure 3Bi-iii).  
In comparison to the data of Bernstein et al. 40 despite the fact that a different ionisation mode 
has been used (negative instead of positive as used here), the CCS values derived are in good 
agreement for each charge state, although the Bernstein data indicates the presence of an 
additional slightly larger conformer. However, the CCS values derived for the [aSyn+/-
10H]10+/- species show a discrepancy. The Bernstein CCS value is ~2500 Å
2 (Figure 4, 40) 
whereas the major peak in our CCSD plot is centred on ~1800 Å2 (Figure 3B). The lower 
intensity shoulder centred at ~2300 Å2, represents a more extended conformer. This suggests 
that we have a cooler source, or we observe a difference resulting from charge location. For 
[aSyn+13H]13+, the CCSD is broad and centred on ~3000 Å2 (Figure 3Ci). This CCSD also 
features a shoulder, attributed a compact conformer. Again the large error bars are consistent 
with a lowly populated species not present in subsequent time points where the intensity 
remains centred on ~3000 Å2 (Figure 3Cii-iii). 
The CCSD at t=0 for the dimer, [(aSyn)2+13H]
13+ is broad, similar to those exhibited for 
highly charged monomeric species. The ATD provides a CCS of ~3000 Å2 (Figure 3Di). 
There is a small shoulder (~3600 Å2), which becomes more intense at Day 3 and is present at 
Day 5 (Figure 3Dii-iii). The shoulder is obscured on the [(aSyn)2+13H]
13+ Day 5 CCSD 
(Figure 3Diii) by the broadening of the initial peak (~3000 Å2). For the higher charged dimer 
[(aSyn)2+17H]
17+ at t=0, the CCSD observed is again broad and centred on ~3900 Å2 with a 
shoulder centred on ~3200 Å2 (Figure 3Ei). This CCSD highlights the variability in the 
populations in the sample, the large error bars which are present across the CCSD suggesting 
several lowly populated conformationally dynamic species. 
These species were chosen as they represent the breadth of the CSD, remain present 
throughout the time course, and represent the multimodal distribution present (Supplementary 
information Figure S3). They are representative of the CSSD of all observed species from 7 < 
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z < 22 (data not shown). The large spread in CCS over the entire CSD, ∆CCS ~1600 Å2 (See 
Figure 3Ai and Figure 3Ci) and the large spread in CCS for each charge state (Figure 3A-E) 
suggests the protein is flexible in solution and can adopt multiple conformations in solution 
and gas phase. The average CCS for both monomers and dimers increases with charge state, 
which we attribute to extended, more solvent exposed and therefore higher protonated forms 
of the protein in solution an effect which will be exacerbated by Coulombic repulsion in the 
gas phase as reported previously 75. The TEM data of samples subjected to the same solution 
and environmental conditions, show no fibrils at t=0 (Supplementary information Figure 
S2A). 
There is a notable lack of change in CCS across the incubation timecourse (Figure 3) despite 
the appearance of fibrils in the solution over the same time (Supplementary information 
Figure S2B). The narrow CCSD centred on ~1400 Å2 at t= 0 for [aSyn+6H]6+, remains 
centred on ~1400 Å2, at t=3 days and t=5 days (Figure 3Ai-iii). The pattern is repeated for 
higher charged species, at t=0 for [aSyn+13H]13+ (Figure 3Ci), the CCSDs is centred on 
~3000 Å2, and remains so at t=3 days and t=5 days (Figure 3Cii and ii, respectively). There is 
also no evidence for narrowing of the CCSD which would indicate the adoption of a specific 
conformer. This pattern is also repeated for the dimeric species, see Figure 3Ei-iii; the most 
intense peak remains centred on ~3900 Å2 and the large error bars of the dimer CCSDs 
indicate that α-synuclein remains flexible. This suggests that even at long times, the solution 
contains conformationally dynamic components, which perhaps exist in rapid equilibrium 
between oligomeric species, prior to their sequestration into larger oligomers or even fibrils. 
Such species are likely to reorganise during the ESI and even the IM experimental timescales, 
although with time there is less variability, as evidenced by smaller error bars (Figure 3ci and 
iii). A comparison of the [aSyn+6H]6+ monomer and the [(aSyn)2+13H]
13+ dimer (Figure 3) 
shows no significant decrease in CCS with dimer formation. The similar number of charges, 
with respect to mass, limits any difference that could be attributed to Coulombic repulsion. 
This lack of any compaction suggests that the α-synuclein dimer has a small binding 
interaction site and remains a largely unstructured dimer, or the superposition of many forms. 
This conclusion concurs with the force spectroscopy studies of α-synuclein dimers of 
Neupane et al. 76  who describe a lack of discrete cooperative unfolding events for most 
dimers, indicative of lack of structure. In a small number of cases ~15%, they note multiple 
unfolding transitions, which is supportive of the number of broad conformational families as 
well as the day to day variation shown by our MS and IM-MS experiments 76. The observable 
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monomer and dimer species, which dominate the mass spectrum possess a large 
conformational spread which does not alter significantly during aggregation. This is despite 
the evidence from TEM (Supplementary information Figure S1B) that these solutions contain 
fibrils, suggesting that the conformations of the soluble feeder stock of the aggregated 
solution is not altered by it (or at least not that can be observed by this method), or that the 
fibrils reversibly disassemble during desolvation. This second explanation is less likely since 
the solutions become harder to spray along the aggregation time course, indicating the 
presence of aggregates that block the spray tips. 
3. Crosslinking IM-MS to trap solution phase conformers  
Following the use of the cross linking reagent, extensive cross linking was seen for 
monomeric α-synuclein as shown in Supplementary Information Figure S4. Data for the 
dimers was not of sufficient intensity and was at too poor resolution to obtain collision cross-
section data due to intensity stealing by the different masses of each cross linked form. 
CCSDs are derived from the arrival time distributions for selected charge states following 
exposure to the crosslinking reagent are shown in Figure 4. Analysis of the CCSDs in Figure 
4 shows three conformational families. The first, designated C1, is centred at ~1200 Å2 and is 
most clearly visible in the [aSyn+6H]6+ CCSD (Figure 4Ai). This compact conformer is 
present and remains populous even following the addition of eleven modifications (Figure 
4Aiv). The second family of a more extended conformer, E1 is centred at ~1500 Å2 and is 
clearly visible in the [aSyn+6H]6+ CCSD (Figure 4Aiii - iv) and remains present throughout 
the intervening charge states ([aSyn+7H]7+ to [aSyn+9H]9+)  to the [aSyn+10H]10+ (Figure 
4E). This extended conformer is stabilised by the addition of more crosslink modifications 
(See Figure 4Aiii - iv, [aSyn+6H]6+ CCSD) and remains the dominant conformer. This 
conformational family matches the Bernstein et al. CCS value for the [aSyn-8H]8-. The third 
family, U1 centred at ~2350 Å2 is most clearly visible in the [aSyn+10H]10+ CCSD. This 
unfolded conformer is again stabilised by the addition of crosslink modifications, shown by 
the gradual defining of the peak in the [aSyn+10H]10+ CCSD (Figure 4Ei – iv) and to a 
smaller extent in the 10 and 11 modification CCSDs of the [aSyn+9H]9+ charge state (Figure 
4Diii – iv). The small CCS difference between [aSyn+6H]6+ and [aSyn+10H]10+ is likely to 
result from the additional coulombic repulsion suffered by the [aSyn+10H]10+ species.  
The ability of the crosslinker modification to restrict the flexibility of the protein can be seen 
from the narrowing of the charge state distribution (Supplementary Information Figure S4). 
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This effect can also be seen clearly in the CCSD of single charge state for example that of 
[aSyn+7H]7+ (Figure 4Bi) where narrowing of the CCSD occurs with the addition of as few 
as four crosslinking modifications and more dramatically with eleven (Figure 4Biv). This 
narrowing suggests the crosslinks are preventing the protein from collapsing, preventing the 
adoption of compact CCS values as displayed in the unmodified sample (See Figure 4Biv) in 
addition to decreasing the population of conformers sampled. The same effect is also evident 
in the CCSDs for other higher charge states including [aSyn+8H]8+, however highly charged 
species such as [aSyn+10H]10+, both unmodified and modified (eleven crosslink 
modifications, Figure 4Eiv) exhibit the same most collapsed state (~1200 Å2), suggesting 
coulombic repulsion is preventing the complete collapse of the protein which we have 
previously predicted to be 806 Å2 77. Interestingly, at higher charge states, the crosslinked 
protein transfers both compact and extended species (Figure 4Eiv).  
4. ECD – top down sequencing of an IDP 
Here we examine the effect of pH on α-synuclein using ECD-FT-ICR MS. ECD is a well-
established tool for top-down sequencing of proteins and determination of the position of post 
translational modifications, information on higher order structure can also be obtained 78. 
ECD has been previously applied to α-synuclein to investigate its interaction with the 
naturally occurring polyamine, spermine 63, 79.  Xie et al. 79 focussed on [aSyn+14H]14+, since 
the fragmentation efficiency is far higher for higher charge states. The FT-ICR MS mass 
spectrum is shown in supplementary information Figure S5.  Here we examine the fragments 
from selecedt low charge state monomers, [aSyn+6H]6+ to [aSyn+10H]10+ at pH 6.8 and 
[aSyn+7H]7+ to [aSyn+9H]9+ at pH 3.5 (Select annotated fragmentation spectra, 
Supplementary Information Figure S6-S9). The fragments from select non-mass coincident 
dimer species are also examined, with charge states spanning from [(aSyn)2+13H]
13+ to 
[(aSyn)2+17H]
17+ (Select annotated fragmentation spectra, Supplementary Information Figure 
S10-S12). 
Decreasing the pH from 6.8 to 3.5 led to an increase in fragmentation efficiency. There is an 
increase in the intensity of fragments at pH 3.5 for both monomer and dimer species, which 
suggests the protein has adopted a less compact form with fewer stabilising non-covalent 
interactions, more susceptible to ECD. This is at variance with reported IM-MS data which 
describes the partial collapse of the protein at pH 2.5, a result of the acidic C-terminus being 
liable to collapse upon protonation40 and far-UV CD, FTIR, ANS fluorescence and SAXS 
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data which demonstrate an increase in structure with a decrease in pH 72. Although the 
fragmentation pattern appears similar, the majority of fragments resolved for the pH 6.8 
sample are from the [aSyn+10H]10+ charge state. This charge state has been shown via IM-
MS to exhibit an extended and therefore fragmentation-susceptible conformation. The 
comparison of [aSyn+7H]7+ to [aSyn+9H]9+ charge states (Figure 5 and Table 1) for both 
pHs, highlight the difference in fragmentation with pH. The increase in fragments seen under 
low solution pH conditions could be a result of the extension of the N-terminus, which has 
been shown to adopt a more extended form at low pH, in contrast to the collapse experienced 
by the C-terminal region 80 
For both monomeric and dimeric parent ions, the fragmentation is limited to the N-terminus 
of the protein, both at pH 6.8 and 3.5. C-terminal fragments are only observed for the 
[aSyn+10H]10+ monomer at pH 6.8 (Figure 5A). If the α-synuclein monomers [aSyn+7H]7+ to 
[aSyn+9H]9+ at pH 6.8 and 3.5 are considered, no fragmentation is found from Gly47 to 
Ala140 at pH 6.8 (Figure 5A) and between Ala76 to Ala140 at pH 3.5 (Figure 5B).  
Similarly, for the α-synuclein dimers, limited C-terminal fragmentation occurs (Table 1). 
This data suggests that under these conditions there is a stable protected core of the protein 
involving the C-terminus, this correlates with paramagnetic relaxation enhancement and 
NMR dipolar couplings which demonstrate the presence of long range interactions between 
the C-terminus and central region of α-synuclein 81, 82. In the case of the dimer, this suggests 
this may be the region of the dimer interface, which is supported by findings from single 
molecule AFM force spectroscopy measurements83.  However, our results do not correlate 
with other published data from CD, FTIR and in-cell NMR 35 nor with data from HDX MS 
studies 56, 58, which suggest independently a C-termini which is either, protected or 
unprotected from HDX exchange due to the presence of secondary or higher structure, 
highlighting the highly dynamic nature of α-synuclein, in particular the C-terminus. 
Discussion and Outlook 
α-synuclein is known to be an extraordinarily conformational plastic protein, characteristic of 
its intrinsically disordered nature. Our MS data expands on these previous studies, 
highlighting the presence of multiple conformational families and emphasising the 
susceptibility of α-synuclein to environmental changes such as pH as well as highlighting the 
day to day variability of our subject. The aggregation of α-synuclein is strongly linked to the 
aetiology of Parkinson’s disease; we have demonstrated the ability of MS to follow in vitro 
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aggregation of α-synuclein, through the depletion of the solution phase constituents. This 
method with little modification will allow the high throughput prototyping of potential 
aggregation inhibitors, due to the non-discriminatory nature of the technique, a prerequisite 
for studying the complex aggregation pathways of α-synuclein, as previously highlighted by 
HDX-MS 59. IM-MS shows a lack of a CCS change with aggregation duration, suggesting 
that the species in the solution phase remain disordered, adopting aggregation related 
conformational modifications at the time of sequestration into oligomeric or fibrillar species. 
This agrees with the intrinsically disordered nature of α-synuclein.  
The use of gas phase techniques has prompted understandable concern as to the biological 
relevance of these measurements in comparison with solution assays. Here we have shown 
that chemical crosslinking can be used to trap solution phase species prior to gas phase 
analysis. Following chemical crosslinking we have identified three stable conformational 
families, compact (~1200 Å2), ecxtended (~1500 Å2) and unfolded (~2350 Å2) which are also 
present in the uncrosslinked protein albeit at differing abundances. When we extrapolate these 
values to anticipated Radius of Gyration (Rg) values from solution (Supplementary 
information Figure S14 and Table S1, we find that these correlate to 16.8, 26.5, and 54.1 Å, 
these values compare well with Rg values calculated for fully globular and random coil 140 
amino acid polypeptide chains, of 15.1 Å and 52.1 Å, respectively and the Rg range 
established encompasses reported experimental Rg values 
72.  This agreement supports the use 
of gas phase techniques of intact proteins to as a probe of solution conformers.  
ECD has been established elsewhere as a technique to probe the location of structure within 
gas phase protein ions. The large day to day and sample to sample variability of α-synuclein 
even under tight control could explain the increase in fragmentation efficiency that occurs 
with dropping the solution pH, a result that contradicts trends observed by multiple structural 
techniques. Alternatively, this increased fragmentation exhibited at low pH may be a result of 
the remodelling of α-synuclein. At neutral pH, α-synuclein has been shown to exhibit 
compact, intermediate and extended conformers by our MS, IM-MS and crosslinking IM-MS 
data and other studies including Frimpong et al. 41. Bernstein et al. identify conformer 
collapse at pH 2.5 40, which concurs with measurements from other biophysical techniques. 
In line with the work of Frimpong et al. 41 and Ferreon et al.84, 85 scanning through a solution 
condition such as pH or SDS concentration enables access to intermediate conformations of 
the folding landscape, in our study the pH was lowered to pH 3.5 40, enabling access to 
intermediate conformations such as those identified in 41. The conformational remodelling of 
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α-synuclein has previously been shown to be substantial, even following small changes; for 
example, see the unfolding event between the -8 and -9 charge states in 40. We therefore 
theorise this increase in fragmentation is not the  result of the low pH disrupting long range 
interactions which lock α-synuclein in a semi-flexible state 81, 82, 86, but rather the induction of 
large scale conformational remodelling induced by modifying the solution environment. This 
is a similar effect to that seen by Frimpong et al. via deconvolution of α-synuclein CSDs at 
increasing pH 41, prior to protein collapse at lower pH (Bernstein et al. 40), this intermediate 
ensemble stage facilitates the greater fragmentation seen at low pH. 
The conformational fluidity of α-synuclein, will and does slow the progress of our 
understanding of this system with all assays, despite this. MS based techniques can be 
usefully applied both to obtain structural information and also to follow the complex 
heterogeneous early stages of aggregation of an this amyloidogenic protein. 
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Figure Captions 
Figure 1 
Comparison of nESI-MS data of α-synuclein (1mg/mL) (50mM ammonium acetate). A & B. 
α-synuclein pH 6.8, spectra taken under similar instrumental and identical sample conditions. 
C. α-synuclein pH 3.5,  D. α-synuclein pH 6.8 post-96 hour aggregation. N.b. the x-axis scale 
is enlarged for C to reflect the lower charge states displayed. 
Figure 2 
A plot of the monomer: dimer ratio derived from the average sum of the intensity of all 
monomer and dimer peaks of three independent experiments following an aggregation time 
course. 
Figure 3 
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CCS distributions for the A: [aSyn+6H]6+, B: [aSyn+10H]13+, C: [aSyn+13H]13+ monomer 
species and for D: [(aSyn)2+13H]
13+, and E: [(aSyn)2+17H]
17+, dimer species. The data 
presented was recorded with 35V across the drift cell. 
Figure 4 
CCS distributions of α-synuclein with and without crosslinking. The dashed (Black) line on 
each CCSD corresponds to the CCSD derived for each charge state from an un-modified α-
synuclein sample run on the instrument intended for comparison. The solid line on each 
CCSD corresponds to the CCSD derived for each charge state from a cross linked α-
synuclein sample, ordered by increasing number of crosslink modifications, (i) 4 
modifications, (ii) 6 modifications, (iii) 10 modifications and (iv) 11 modifications. The 
number of modifications relate to the number of crosslinks present which are a mixture of 
complete crosslinks and dead end crosslinks. These plots demonstrate the effect of 
crosslinking and charge state on the conformational constriction of α-synuclein. All data was 
taken with 30V across the drift cell. 
Figure 5 
ECD fragmentation map for α-synuclein monomers at pH 6.8 (A) and pH 3.5 (B). 
Fragmentation efficiency is increased at low pH and increases with charge state.  
Figure 1 
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Figure 3 
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Figure 4  
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Table 1 Caption  
The fragmentation map from α-synuclein dimers where z =13+, 15+ and 17+ at pH 3.5 and 
pH 6.8. 13+ fragments are underlined, 15+ fragments are in brackets and 17+ fragments are 
in bold. Resolution of the fragment from multiple charge states is identified by combining the 
typography emphasis styles. 
 
Table 1 
pH 6.8 pH 3.5 
13+/(15+)/17+ 13+/(15+)/17+ 
C ion Z ion C ion Z ion 
(C115)  C279 (Z274) 
(C57)  C149  
C35  C98  
(C6)  C75  
  C50  
  C47  
  (C46)  
  C39  
  (C38)  
  C37  
  C35  
  C34  
  (C27)  
  (C24)  
  (C23)  
  (C22)  
  (C21)  
  C11  
  (C9)  
  (C6)  
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